About Us

About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call

By: StockStory

COLL Cover Image

Collegium Pharmaceutical’s second quarter results drew a positive market response, as management credited the performance to record revenues from its ADHD therapy Jornay and steady growth across its pain portfolio. CEO Vikram Karnani highlighted that Jornay prescriptions grew 23% year over year, fueled by expanded sales force efforts and targeted marketing initiatives. The company also noted that all three of its core pain medications delivered year-over-year revenue growth, underpinning the robust financial outcome. Management attributed the quarter’s success to continued execution on commercial expansion and the integration of new assets, as well as initial benefits from investments in awareness and prescriber outreach.

Is now the time to buy COLL? Find out in our full research report (it’s free).

Collegium Pharmaceutical (COLL) Q2 CY2025 Highlights:

  • Revenue: $188 million vs analyst estimates of $180.4 million (29.4% year-on-year growth, 4.2% beat)
  • Adjusted EPS: $1.68 vs analyst expectations of $1.85 (9.2% miss)
  • Adjusted EBITDA: $105.1 million vs analyst estimates of $103.7 million (55.9% margin, 1.4% beat)
  • The company lifted its revenue guidance for the full year to $752.5 million at the midpoint from $742.5 million, a 1.3% increase
  • EBITDA guidance for the full year is $447.5 million at the midpoint, above analyst estimates of $437.6 million
  • Operating Margin: 18.7%, down from 32.7% in the same quarter last year
  • Market Capitalization: $1.19 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call

  • Leszek Sulewski (Truist Securities) asked about the targeted increase in prescribers for Jornay and the potential to revisit peak sales estimates. CEO Vikram Karnani said the company will reassess forecasts after evaluating the impact of sales force expansion and marketing investments, while Chief Commercial Officer Scott Dreyer emphasized ongoing growth in prescriber breadth and awareness.
  • Sulewski (Truist Securities) also questioned additional investments planned for the pain portfolio. Dreyer responded that investments remain steady and focused on maintaining current brand performance, with no significant shifts expected in sales or marketing spend.
  • John Todaro (Needham & Company) inquired about specific strategies to boost Jornay’s performance during the third quarter and competitive risks in the pain franchise. Dreyer highlighted the focus on awareness campaigns and leveraging the expanded sales team, while CFO Colleen Tupper detailed the regulatory and manufacturing hurdles that limit near-term generic competition.
  • David A. Amsellem (Piper Sandler) asked about the company’s approach to business development and whether it would consider non-pain or earlier-stage assets. Karnani stated the primary focus remains on commercial or commercial-ready assets that leverage existing infrastructure, with openness to other areas only under disciplined financial criteria.
  • Amsellem (Piper Sandler) also questioned the timing for pursuing pipeline or development-stage assets. Karnani indicated this could be considered after further portfolio expansion and scaling the business, but not in the immediate term.

Catalysts in Upcoming Quarters

In future quarters, our analysts will watch (1) the effectiveness of new sales and marketing initiatives in driving sustained prescription growth for Jornay, particularly as the back-to-school season unfolds, (2) how operating expense trends evolve as commercialization investments mature, and (3) any developments in potential generic entry timelines for the pain portfolio. Management’s execution on business development and capital deployment will also be key indicators of progress toward diversification goals.

Collegium Pharmaceutical currently trades at $38.35, up from $29.72 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

More News

View More
3 Overlooked Value Stocks Set to Surge as Rates Drop
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers CAVA CMG LULU UPS
Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
Via MarketBeat
Topics Economy
Tickers HIMS
After the Fed's Rate Cut, PNC Could See a Mortgage Refinance Boom
Via MarketBeat
Topics Economy
Tickers PNC
AIRO Group's Pullback: An Undervalued Growth Opportunity?
Via MarketBeat
Topics Supply Chain
Tickers AIRO
Caterpillar Stock Hits All-Time High—Is There More Room to Run?
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Tickers CAT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.